AUTHORS
Danni Cai, Xiaolin Xu2, Wei Dai3, Wenqi Fang4, Maoqing Tan5, Huifang Huang, PhD6
AFFILIATIONS
1 Central Laboratory, Fujian Medical University Union Hospital, Fuzhou, China
2 Central Laboratory, Fujian Medical University Union Hospital, Fuzhou, China
3 Central Laboratory, Fujian Medical University Union Hospital, Fuzhou, China
4 Central Laboratory, Fujian Medical University Union Hospital, Fuzhou, China
5 Central Laboratory, Fujian Medical University Union Hospital, Fuzhou, China
6 Central Laboratory, Fujian Medical University Union Hospital, Fuzhou, China
ABSTRACT
Acute myeloid leukemia (AML) is a clonal hematopoietic malignancy in which relapse and refractory disease remain major causes of treatment failure. The bone marrow microenvironment (BMM) supports leukemic metabolic adaptation under cytotoxic stress, in part by enabling bone marrow stromal cells (BMSCs) to transfer functional mitochondria to AML cells and sustain oxidative phosphorylation. Although this intercellular mitochondrial transfer is well documented, the leukemia-derived signals that compel donor BMSCs to mobilize and supply mitochondria remain poorly defined. The preferential acquisition of stromal mitochondria by AML cells suggests that leukemic cells actively reprogram BMSCs into a donor-side mitochondrial supply state.
Targeted metabolomic profiling of syngeneic MLL-AF9 and AML1-ETO9a models revealed elevated fumarate levels in both bone marrow flush fluid and murine BMSCs relative to healthy controls. Human validation showed elevated fumarate levels in bone marrow plasma from patients with newly diagnosed AML (n = 71) compared with non-leukemic controls (n = 10), as well as in patient-derived BMSCs following reconstituted autologous co-culture (AML, n = 30; controls, n = 10). The absence of changes in BMSC SDH or FH expression and activity suggested an extrinsic source. Pharmacologic SDH inhibition or SDHA knockdown reduced intracellular fumarate generation and extracellular release by AML cells, with a corresponding decrease in fumarate accumulation in co-cultured BMSCs, whereas FH knockdown produced the reciprocal effects. Consistently, ¹³C6-glucose isotope tracing showed that SDHA knockdown reduced both the release of AML-cell-derived ¹³C4-fumarate into the supernatant and its subsequent accumulation in BMSCs, while FH knockdown caused the opposite changes, establishing AML cells as the principal source of excess fumarate in the leukemic niche. In a prospective cohort of 71 patients with newly diagnosed AML, patients with high bone marrow plasma fumarate had a lower complete remission rate than those with low fumarate levels (41.67% vs 77.14%). High fumarate remained independently associated with failure to achieve remission after adjustment for bone marrow blast percentage and ELN 2022 risk category (OR = 3.88, P = .024). Together, these findings establish AML-cell-derived fumarate as a prominent metabolic feature of the leukemic niche and link its accumulation to inferior induction response.
RNA sequencing of an independent cohort (n = 3 per group) revealed enrichment of mitochondrial biogenesis programs in BMSCs from patients with AML (AML-BMSCs) relative to healthy donor BMSCs (HD-BMSCs). Exogenous fumarate increased respiratory-chain protein expression, mtDNA copy number, and mitochondrial content in BMSCs, and dose-dependently enhanced BMSC-to-AML mitochondrial transfer, OXPHOS in recipient AML cells, and cytarabine resistance. Suppression of BMSC mitochondrial biogenesis abrogated the enhanced transfer and chemoresistance. In AML xenografts, bidirectional genetic modulation of leukemic fumarate recapitulated this relationship: FH knockdown increased marrow fumarate, donor-derived murine mtDNA and OXPHOS in human AML cells, impaired cytarabine efficacy, and shortened survival, whereas SDHA knockdown produced the opposite effects.
Mechanistically, SLC13A3 mediated fumarate uptake by BMSCs. Intracellular fumarate stabilized HIF-1α and induced its Cys800 succination, promoting HIF-1α nuclear localization and PPARGC1A transactivation and thereby activating PGC-1α-dependent mitochondrial biogenesis. Loss of SLC13A3, HIF-1α, or PGC-1α blocked fumarate-induced mitochondrial biogenesis and transfer, whereas the HIF-1α C800S mutation impaired fumarate-induced nuclear localization and PPARGC1A activation.
These findings establish AML-cell-derived fumarate as a leukemia-to-stroma metabolic signal that is taken up through SLC13A3 and activates HIF-1α/PGC-1α-dependent mitochondrial biogenesis, thereby reprogramming BMSCs into a mitochondrial donor state. This leukemia-to-stroma metabolic signaling axis couples leukemic fumarate production to stromal mitochondrial supply and chemoresistance, providing a mechanistic framework for targeting microenvironmental metabolic support in AML.
DISCLOSURES
Danni Cai: No relevant conflicts of interest to declare.